Speaker
Description
Targeted alpha therapy is a developing technique that uses alpha-emitting radionuclides combined with selective delivery vectors (peptides, antibodies, nanoparticles). These alpha-emitters deliver highly localized, intense radiation to cancer cells, thereby reducing damage to surrounding healthy cells. This is due to the short distance traveled by the alpha-emitter and the high linear energy transfer, which allows for greater precision. Actinium-225 (Ac-225) is an alpha-emitting radionuclide that has attracted attention in Nuclear Medicine for cancer treatment. Radiopharmaceuticals labeled with this radionuclide can induce breaks in the DNA double helix, inhibiting cell multiplication. Ac-225 generates eight short-lived decay products (Fr-221, At-217, Bi-213, Po-213, Pb-209, and stable Bi-209), emitting four alpha particles along the decay chain up to stable Bi-209, which can deliver a lethal dose to cancer cells. It is important to note that Ac-225 therapy has shown promise, especially in patients who have not had success with other cancer treatments. Despite some promising clinical results, significant research is still needed to optimize the implementation of targeted alpha therapy.Currently, several production routes for Ac-225 are under investigation, but the main clinical source is derived from a Th-232 stock. Ac-225 is isolated using a generator system and supplied with high specific activity. Recently, the U.S. Department of Energy has been regularly producing Ac-225 by scattering high-energy protons (100 MeV or more) off Th-232.Clinically significant quantities of Ac-225 may be generated by irradiating Ra-226 compounds (T1/2 = 1600 y) with low- and medium-energy protons or photons. The main challenges associated with radio compound targets are handling and availability. Ra-226 contains several daughter radionuclides, with Rn-222 (T1/2 = 3.8 d) being an inert, radioactive gas that can significantly hinder target design, handling, and subsequent radiochemistry. Although there are currently no products available from Ra-226, several research centers and commercial companies have been studying this possibility over the past 10 years.
This work aims to obtain quantitative data, through numerical simulations using the Monte Carlo method, to assess the production of Ac-225 by irradiating inorganic Ra-226 compounds with low- to medium-energy proton beams. Six distinct targets were evaluated: purified Ra-226 in metallic form; radium chloride, radium oxide, radium hydroxide, radium carbonate, radium nitrate, and purified radium in metallic form.Simulated irradiations were performed using 30 MeV proton beams for 45 hours at a beam current of 50 μA. The activities of the Ac-225 produced were measured at four time points: at the end of the irradiations (EOB), and at 20, 50, and 100 days after the end of the irradiations.The results showed that the practical production yield of Ac-225 ranged from 1.70 MBq/μAh for the metallic Ra-226 target to 0.70 MBq/μAh for the radium nitrate target, indicating that the metallic Ra-226 target gave the highest yield among the targets evaluated.
| Keywords | Actinium-225 Production; Targeted alpha therapy |
|---|---|
| Proceedings Publication Intent | Yes |
| Student Award Eligibility | yes |
| Financial Support Request | no |